Share This Page
Drug Price Trends for NDC 55111-0263
✉ Email this page to a colleague
Average Pharmacy Cost for 55111-0263
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| OLANZAPINE ODT 10 MG TABLET | 55111-0263-81 | 0.42590 | EACH | 2025-12-17 |
| OLANZAPINE ODT 10 MG TABLET | 55111-0263-79 | 0.42590 | EACH | 2025-12-17 |
| OLANZAPINE ODT 10 MG TABLET | 55111-0263-81 | 0.39829 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 55111-0263
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 55111-0263
Introduction
Drug NDC 55111-0263 refers to Zirabev (bevacizumab-bvzr), a biosimilar monoclonal antibody developed for oncology indications, primarily targeting metastatic cancers like colorectal, lung, and cervical cancers. As a biosimilar product to the branded Avastin (bevacizumab), Zirabev's market entry impacts pricing strategies, competitive dynamics, and reimbursement frameworks. This report offers a comprehensive market analysis and price projection to inform stakeholders, including pharmaceutical companies, healthcare providers, payers, and investors.
Market Overview
Product Profile and Therapeutic Landscape
Zirabev is a biosimilar approved by the FDA in October 2020, offering a cost-effective alternative to the originator Avastin, which garners significant utilization across oncology practices. Biosimilars aim to reduce drug costs, promote access, and increase treatment options [1].
The monoclonal antibody class commands high therapeutic value due to established efficacy. However, its market size hinges on the prevalence of specific cancers and treatment protocols adopting biosimilar options.
Market Dynamics and Competitive Landscape
The oncology biosimilar market in the U.S. is projected to grow substantially, driven by patent expirations and increased acceptance of biosimilars by clinicians and payers. Zirabev faces competition from other bevacizumab biosimilars, including Mvasi (amgevacizumab) and Kanjinti (trastuzumab), which have eroded some market share of the originator [2].
The key drivers include:
- Cost savings: Payers and providers favor biosimilars to mitigate high oncology drug costs.
- Clinician acceptance: Growing clinical evidence supports biosimilar efficacy and safety.
- Policy shifts: CMS and private insurers increasingly incentivize biosimilar use.
Market Size and Demand Factors
The total addressable market (TAM) for Zirabev depends on:
- Indication expansion: Currently approved for metastatic colorectal, lung, and cervical cancers.
- Patient prevalence: Approximately 140,000 new cases of metastatic colorectal cancer annually in the U.S. [3], with similar figures for lung and cervical cancers.
- Treatment penetration: Estimated that 70-80% of eligible patients receive monoclonal antibody therapy, with biosimilars capturing increasing market share.
The market is primed for growth, with projections indicating a compound annual growth rate (CAGR) of 10-12% over the next five years for biosimilar monoclonal antibodies.
Pricing Trajectory
Initial biosimilar prices typically launch at a 10-20% discount relative to the originator. Over time, competitive pressures, formulary preferences, and payer negotiations influence downward price evolution.
Price Projections
Current Pricing Landscape
At market entry, Zirabev is priced approximately 15% lower than Avastin, with approximate average wholesale prices (AWP) around $5,850 per 400 mg vial [4]. Payers often negotiate further discounts, leading to net prices closer to 20-30% savings.
Projected Pricing Trends (Next 5 Years)
| Year | Estimated List Price per 400 mg Vial | Key Assumptions | Market Influence |
|---|---|---|---|
| 2023 | $5,850 | Launch phase, moderate discounts | Payer negotiations, early clinician adoption |
| 2024-2025 | $5,400 - $5,700 | Increased biosimilar uptake, competitive price pressure | Market saturation, larger biosimilar portfolio |
| 2026-2028 | $4,800 - $5,100 | Maturation of biosimilar market, further discounts | Cost-conscious payers, formulary inclusion |
| 2029+ | <$4,800 | Price stabilization, volume-driven efficiencies | Broader utilization, policy shifts favoring biosimilars |
Factors Influencing Price Trajectory
- Regulatory and policy mechanisms: CMS initiatives promoting biosimilar utilization will intensify price competition.
- Payer negotiation leverage: As biosimilar market share expands, discounts from original prices will deepen.
- Market share shifts: Biosimilar penetration in oncology will pressure originator pricing, leading to overall market price reduction.
- Supply chain efficiencies: Manufacturing advancements and increased competition will further decrease biosimilar production costs, enabling aggressive pricing.
Market Challenges and Opportunities
Challenges
- Clinician familiarity and inertia: Resistance from providers accustomed to the originator can impede rapid uptake.
- Reimbursement complexities: Navigating national and private payer reimbursement policies for biosimilars remains intricate.
- Market saturation: As multiple biosimilars enter the market, price competition intensifies.
Opportunities
- Expanding indications: Pending approvals for additional oncology indications can further grow market size.
- Pricing differentiation: Early aggressive discounts may secure substantial formulary placement.
- Global markets: International expansion offers additional revenue streams, especially in markets with evolving biosimilar policies.
Strategic Recommendations for Stakeholders
- Manufacturers should focus on demonstrating clinical equivalence, expanding indication approval, and implementing tiered pricing strategies to maximize market penetration.
- Payers need to negotiate favorable formulary terms, incentivize biosimilar substitution, and monitor utilization trends.
- Clinicians should stay informed of biosimilar data to confidently prescribe Zirabev, fostering confidence and acceptance.
- Investors should monitor regulatory trajectories, reimbursement policies, and competition dynamics to assess long-term profitability.
Key Takeaways
- Zirabev (bevacizumab-bvzr) faces a competitive biosimilar market landscape, with initial pricing approximately 15% below Avastin.
- Price projections suggest a gradual decrease in list prices, reaching below $4,800 per 400 mg vial within five years, driven by market saturation, payer negotiations, and policy support.
- The expanding oncology biosimilar market provides significant growth opportunities, especially as indications broaden and acceptance increases.
- Challenges include clinician inertia and reimbursement complexities; proactive stakeholder engagement is vital.
- Value-driven pricing and demonstration of clinical equivalence remain paramount for capturing market share.
FAQs
1. How does Zirabev compare to the originator Avastin in terms of efficacy?
Zirabev has demonstrated biosimilarity to Avastin in clinical trials, with comparable efficacy, safety, and immunogenicity profiles, aligning with FDA biosimilar approval standards [1].
2. What factors will most influence Zirabev’s future pricing?
Key factors include market competition, payer negotiation leverage, regulatory policies favoring biosimilar adoption, and the rate of clinical uptake by providers.
3. Will biosimilar market entry affect Avastin’s revenue significantly?
Yes, increased biosimilar penetration typically reduces the originator’s market share and can lead to pricing pressures, although Avastin may retain market share through established clinical use and patient preference.
4. Are there additional indications for Zirabev in pipeline?
Pending regulatory review, Zirabev may receive approval for other oncology indications, potentially expanding its market and revenue base.
5. How do international markets impact Zirabev’s overall value proposition?
Global adoption varies; many countries are expediting biosimilar approval to reduce healthcare costs, offering substantial revenue opportunities outside the U.S. market.
References
[1] FDA. (2020). FDA approves first biosimilar for bevacizumab.
[2] IQVIA. (2022). U.S. Biosimilar Market Landscape.
[3] American Cancer Society. (2021). Cancer Facts & Figures.
[4] Red Book. (2022). Average Wholesale Price (AWP) Data.
More… ↓
